IPG-CITALOPRAM TABLET

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

CITALOPRAM (CITALOPRAM HYDROBROMIDE)

Pieejams no:

MARCAN PHARMACEUTICALS INC

ATĶ kods:

N06AB04

SNN (starptautisko nepatentēto nosaukumu):

CITALOPRAM

Deva:

40MG

Zāļu forma:

TABLET

Kompozīcija:

CITALOPRAM (CITALOPRAM HYDROBROMIDE) 40MG

Ievadīšanas:

ORAL

Vienības iepakojumā:

100

Receptes veids:

Prescription

Ārstniecības joma:

SELECTIVE-SEROTONIN REUPTAKE INHIBITORS

Produktu pārskats:

Active ingredient group (AIG) number: 0136243002; AHFS:

Autorizācija statuss:

APPROVED

Autorizācija datums:

2016-11-17

Produkta apraksts

_IPG-CITALOPRAM (_
_citalopram hydrobromide) Product Monograph _
_Page 1 of 45 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION
INFORMATION
PR
IPG-CITALOPRAM
®
Citalopram tablets
Tablets, 10, 20 and 40 mg citalopram (as citalopram hydrobromide),
Oral
USP
Antidepressant
Marcan Pharmaceuticals Inc.
2 Gurdwara Road, Suite #112,
Ottawa, Ontario
Canada, K2E 1A2
Date of Initial Authorization:
NOV 17, 2016
Date of Revision:
July 29, 2022
Submission Control Number: 261614
_IPG-CITALOPRAM (_
_citalopram hydrobromide) Product Monograph _
_Page 2 of 45 _
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS, Hematologic
07/2022
7 WARNINGS AND PRECAUTIONS, Reproductive Health:
Female and Male Potential
07/2022
7 WARNINGS AND PRECAUTIONS, 7.1.1 Pregnant Women
07/2022
TABLE OF CONTENTS
Sections or subsections that are not applicable at the time of
authorization are not listed.
RECENT MAJOR LABEL CHANGES
...............................................................................
2
TABLE OF
CONTENTS......................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORM ATION
...................................................... 4
1
INDICATIONS
..........................................................................................................
4
1.1
Pediatrics
.........................................................................................................
4
1.2
Geriatrics
.........................................................................................................
4
2
CONTRAINDICATIONS
..........................................................................................
4
4
DOSAGE AND ADMINISTRATION
........................................................................
5
4.1
Dosing Considerations
....................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
............................................. 6
4.4
Administration...................................